NDC product
Nitisinone
NDC 0254-3022 · Par Health USA, LLC
Key facts
| Product NDC | 0254-3022 |
|---|---|
| Proprietary name | Nitisinone |
| Nonproprietary name | Nitisinone |
| Substances | NITISINONE |
| Dosage form | CAPSULE |
| Route | ORAL |
| Labeler | Par Health USA, LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA211041 |
| Pharmacologic classes | 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor [EPC], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 2E1 Inducers [MoA], Hydroxyphenylpyruvate Dioxygenase Inhibitors [MoA], Organic Anion Transporter 1 Inhibitors [MoA], Organic Anion Transporter 3 Inhibitors [MoA] |
| Marketing start | Oct 4, 2019 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: